Facebook
Twitter
Telegram
Report an ErrorRigel Pharmaceuticals Balance Sheet 2011-2024 | RIGL
Annual Balance Sheet Rigel Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
27.9 M | -22.4 M | -8.24 M | -1.94 M | 62.8 M | -76.3 M | -38.3 M | -17.6 M | -43.5 M | -15.2 M | -20.9 M | -33.5 M | -18.6 M |
Long Term Debt |
60 M | 972 K | 759 K | 19.8 M | 9.81 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
692 K | 1.13 M | 9.89 M | 8.62 M | 7.27 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 35.5 M | 1.5 M | 128 K | 519 K | 6.57 M | 11.9 M | 7.51 M | 8.74 M | 9.43 M |
Total Current Liabilities |
53.3 M | 65.2 M | 63.6 M | 40.8 M | 58.2 M | 27.7 M | 18.3 M | 22.6 M | 33.8 M | 14 M | 10.3 M | 12.2 M | 11.5 M |
Total Liabilities |
146 M | 148 M | 137 M | 76.4 M | 93.8 M | 29.2 M | 18.5 M | 23.1 M | 40.4 M | 25.9 M | 17.8 M | 20.9 M | 21 M |
Deferred Revenue |
1.36 M | 1.37 M | 2.6 M | 3.02 M | 25.3 M | 1.03 M | - | - | 13.4 M | - | - | 666 K | 129 K |
Retained Earnings |
-1.41 B | -1.38 B | -1.32 B | -1.31 B | -1.28 B | -1.21 B | -1.14 B | -1.06 B | -992 M | -940 M | -849 M | -760 M | -661 M |
Total Assets |
117 M | 134 M | 167 M | 110 M | 148 M | 139 M | 119 M | 78.1 M | 132 M | 154 M | 226 M | 310 M | 257 M |
Cash and Cash Equivalents |
32.8 M | 24.5 M | 18.9 M | 30.4 M | 22.5 M | 76.3 M | 38.3 M | 17.6 M | 43.5 M | 15.2 M | 20.9 M | 33.5 M | 18.6 M |
Book Value |
-28.6 M | -13.6 M | 30.4 M | 34 M | 53.8 M | 110 M | 101 M | 55 M | 91.4 M | 128 M | 208 M | 289 M | 236 M |
Total Shareholders Equity |
-28.6 M | -13.6 M | 30.4 M | 34 M | 53.8 M | 110 M | 101 M | 55 M | 91.4 M | 128 M | 208 M | 289 M | 236 M |
All numbers in USD currency
Quarterly Balance Sheet Rigel Pharmaceuticals
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
60 M | 60 M | 60 M | 60 M | 972 K | 40 M | - | 30 M | 759 K | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 10 M | 10 M | 10 M | 19.2 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
158 M | 147 M | 145 M | 148 M | 148 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.36 M | 1.36 M | 1.36 M | 1.37 M | 1.37 M | 1.37 M | - | 2.1 M | 2.6 M | 3.16 M | 5.81 M | 9.5 M | 3.02 M | 3.02 M | 3.02 M | 3.02 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | - | - | - | - | - | - | 3.76 M | 8.59 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105 K | - |
Retained Earnings |
-1.42 B | -1.41 B | -1.4 B | -1.4 B | -1.38 B | -1.38 B | - | -1.35 B | -1.32 B | -1.3 B | -1.28 B | -1.27 B | -1.31 B | -1.31 B | -1.31 B | -1.31 B | -1.28 B | -1.28 B | -1.28 B | -1.28 B | -1.21 B | -1.21 B | -1.21 B | -1.21 B | -1.14 B | -1.14 B | -1.14 B | -1.14 B | -1.06 B | -1.06 B | -1.06 B | -1.06 B | -992 M | -992 M | -992 M | -992 M | -940 M | -940 M | -940 M | -940 M | -849 M | -849 M | -849 M | -849 M | -760 M | -760 M | -760 M | -760 M | -661 M | -661 M | -661 M | -661 M |
Total Assets |
127 M | 115 M | 117 M | 124 M | 134 M | 116 M | - | 149 M | 167 M | 187 M | 202 M | 216 M | 110 M | 110 M | 110 M | 110 M | 148 M | 148 M | 148 M | 148 M | 139 M | 139 M | 139 M | 139 M | 119 M | 119 M | 119 M | 119 M | 78.1 M | 78.1 M | 78.1 M | 78.1 M | 132 M | 132 M | 132 M | 132 M | 154 M | 154 M | 154 M | 154 M | 226 M | 226 M | 226 M | 226 M | 310 M | 310 M | 310 M | 310 M | 257 M | 257 M | 257 M | 257 M |
Cash and Cash Equivalents |
25.6 M | 45.4 M | 48.8 M | 40.3 M | 24.5 M | 29.9 M | 27.2 M | 24.7 M | 18.9 M | 30.4 M | 84.8 M | 20 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 38.3 M | 38.3 M | 38.3 M | 38.3 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M |
Book Value |
-31.7 M | -31.8 M | -28.1 M | -24.3 M | -13.6 M | 116 M | - | 149 M | 167 M | 187 M | 202 M | 216 M | 110 M | 110 M | 110 M | 110 M | 148 M | 148 M | 148 M | 148 M | 139 M | 139 M | 139 M | 139 M | 119 M | 119 M | 119 M | 119 M | 78.1 M | 78.1 M | 78.1 M | 78.1 M | 132 M | 132 M | 132 M | 132 M | 154 M | 154 M | 154 M | 154 M | 226 M | 226 M | 226 M | 226 M | 310 M | 310 M | 310 M | 310 M | 257 M | 257 M | 257 M | 257 M |
Total Shareholders Equity |
-31.7 M | -31.8 M | -28.1 M | -24.3 M | -13.6 M | -19.8 M | -3.68 M | 6.8 M | 30.4 M | 49.7 M | 68.1 M | 78.3 M | 34 M | 34 M | 34 M | 34 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 110 M | 110 M | 110 M | 110 M | 101 M | 101 M | 101 M | 101 M | 55 M | 55 M | 55 M | 55 M | 91.4 M | 91.4 M | 91.4 M | 91.4 M | 128 M | 128 M | 128 M | 128 M | 208 M | 208 M | 208 M | 208 M | 289 M | 289 M | 289 M | 289 M | 236 M | 236 M | 236 M | 236 M |
All numbers in USD currency